Mode
Text Size
Log in / Sign up

Systematic review and meta-analysis finds ventriculosubgaleal shunt safe in premature neonates with posthemorrhagic hydrocephalusTiny brains, big problem solved without permanent surgery

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider VSGS as a safe option for posthemorrhagic hydrocephalus in premature neonates, but evidence is from observational studies.

This systematic review and meta-analysis included 562 premature neonates with posthemorrhagic hydrocephalus due to intraventricular hemorrhage. The intervention assessed was ventriculosubgaleal shunt (VSGS). The primary outcomes included VSGS-related infection, revision, catheter migration, obstruction, CSF leakage, permanent VPS placement, overall mortality, and procedure-related mortality.

Pooled results showed a VSGS-related infection rate of 9% (95%CI: 5% to 12%), revision rate of 4% (95%CI: 0% to 8%), catheter obstruction rate of 2% (95%CI: 0% to 5%), catheter migration rate of 1% (95%CI: 0% to 5%), CSF leakage rate of 6% (95%CI: 3% to 9%), permanent VPS placement rate of 75% (95%CI: 67% to 82%), overall mortality of 10% (95%CI: 4% to 16%), and procedure-related mortality of 1% (95%CI: 0% to 2%).

The authors did not explicitly report limitations, but as a meta-analysis of observational studies, confounding and selection bias are inherent. The practice relevance is that VSGS is identified as a safe and effective option for treating hydrocephalus caused by IVH in premature neonates. However, clinicians should interpret these findings cautiously given the observational nature of the included studies and the lack of a comparator group.

A smarter way to buy time

Instead of rushing to implant a permanent shunt, some hospitals are using a temporary fix. It’s called a ventriculosubgaleal shunt, or VSGS. This small tube drains excess brain fluid into a space just under the scalp. The body slowly absorbs the fluid there. It acts like a natural filter. Think of it like a detour around a flooded road. Instead of rebuilding the whole highway, traffic gets rerouted until the storm passes.

This buys time. Babies grow. Their brains stabilize. The blood in the fluid clears. Only then do doctors consider a permanent shunt. That delay makes a big difference. Infection risk drops. The baby is stronger. The odds of success go up.

Fluid flow like a river blocked by logs

To understand why this matters, picture the brain’s fluid system as a network of rivers. These rivers carry cerebrospinal fluid, which cushions the brain and removes waste. In healthy babies, the fluid flows and gets reabsorbed naturally. But when a brain bleed occurs, it’s like logs jamming a river. The fluid backs up. Pressure builds. The brain swells.

Permanent shunts act like pumps, moving fluid to the belly. But in tiny, fragile preemies, those pumps can get infected or clogged. The body may reject them. The VSGS avoids that by using a gentler method. It doesn’t force fluid far. It just redirects it a short distance. The scalp tissue absorbs it bit by bit, like a sponge.

A new review of 19 studies looked at 562 premature babies who got this temporary shunt. The results are reassuring.

Most babies did well. Only 9% had an infection tied to the shunt. Just 2% had a blockage. Catheter movement was rare, at 1%. Leakage happened in 6%, but most cases were mild. About 4% needed the shunt adjusted. These numbers are low, especially compared to older methods.

Most babies still need a permanent fix

Here’s the catch. While the temporary shunt helps, most babies—about three out of four—still need a permanent shunt later. That’s not a failure. It’s part of the plan. The goal of VSGS isn’t to replace the final surgery. It’s to delay it until the baby is ready.

Overall, 10% of babies in the studies died. But only 1% of those deaths were directly linked to the shunt procedure. That suggests the surgery itself is very safe.

This doesn't mean this treatment is available yet.

Not every hospital uses this method. Some teams may not be trained in placing VSGS. Others may prefer older techniques. But the data is strong enough that more centers are starting to adopt it.

Experts say this approach makes sense. It matches how preemies heal—slowly, with time. Forcing a permanent solution too early often backfires. Letting the baby grow first gives the best shot at a good outcome.

So what does this mean for families? If your baby is born early and develops hydrocephalus, ask about VSGS. It may not be offered everywhere. But it’s a valid, evidence-backed option. It could reduce the risk of infection and give your baby more time to grow.

There are limits to what we know. Most studies were small. Long-term outcomes, like brain development or movement skills, weren’t fully tracked. The data focuses on safety and short-term success. We still need more research on how these children do years later.

Still, the results are promising. For a condition with few good options, even small gains matter.

What happens next? More hospitals may begin training teams in this technique. Researchers will track children over time to see how they develop. Future studies could compare VSGS directly with other methods. Until then, this temporary shunt offers a smarter, gentler way to protect the tiniest brains.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedMay 2026
View Original Abstract ↓
Intraventricular hemorrhage (IVH) is a severe complication in premature neonates, occurring in 25%-30% of cases and often leading to posthemorrhagic hydrocephalus (PHH). When blood clots in the cerebrospinal fluid (CSF), preventing permanent shunt placement, temporary interventions are considered. Ventriculosubgaleal shunt (VSGS) utilizes the subgaleal space to absorb and drain excess CSF, reducing infection risk and allowing hydrocephalus control until the neonate reaches an appropriate weight and CSF clarity. This systematic review and meta-analysis evaluate the safety and efficacy of VSGS in treating neonatal PHH. A systematic review was conducted using Medline, Embase, and Web of Science following Cochrane and PRISMA guidelines. Eligible studies included those with ≥ 4 neonates. The primary outcomes analyzed were VSGS-related infection, VSGS revision, VSGS catheter migration, catheter obstruction, VSGS-related CSF leakage, permanent ventriculoperitoneal shunt (VPS) placement, overall mortality, and procedure-related mortality. A total of nineteen studies, encompassing 562 neonates, were included in our analysis. The pooled VSGS-related infection rate was 9% (95%CI: 5% to 12%). The need for VSGS revision was observed in 4% of cases (95%CI: 0% to 8%). The catheter obstruction rate was 2% (95% CI: 0% to 5%), while VSGS catheter migration occurred in 1% of cases (95%CI: 0% to 5%). VSGS-related CSF leakage was reported in 6% of neonates (95%CI: 3% to 9%). Permanent VPS placement was required in 75% of patients (95%CI: 67% to 82%). The overall mortality rate was 10% (95%CI: 4% to 16%), and the procedure-related mortality rate was 1% (95%CI: 0% to 2%). This systematic review and meta-analysis identified VSGS as a safe and effective option for treating hydrocephalus caused by IVH in premature neonates.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.